企業プロフィール
Blueprint Medicines 株価・ニュース・カタリスト
- ティッカー:
- BPMC
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価変動の要因
Current closing-price context is not available for BPMC.
企業概要
事業概要
Blueprint Medicines is a precision-oncology and rare-disease company with a strong focus on kinase biology and mast-cell disease.
所在地とセクター分類
Headquartered in the United States and listed on NASDAQ, Blueprint sits in targeted-therapy biotechnology.
ビジネスモデルの特徴
Its model combines commercial product growth, targeted oncology development, and continued investment in rare-disease programs.
バイオ業界での位置付け
Blueprint is a high-quality targeted-therapy biotech whose stock reacts to launches, data, and strategic optionality.
今後のカタリスト
- Blueprint Medicines's catalysts are Ayvakit in systemic mastocytosis and BLU-808 as the next immunology growth option. The market will care about whether the mast-cell franchise can keep expanding while the next program de-risks the pipeline.
最近のニュース
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。